PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of …
Akari Therapeutics Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
– Video webcast now available on-demand BOSTON and LONDON – July 22, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company …
Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its RecentlyGranted India Patent
Access the “What This Means” segment here BOSTON and LONDON – June 25, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company …
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India
Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune …
Notice of Annual General Meeting of Shareholders (AGM) to be held on June 30, 2025
AGM VOTING RESULTS (FORM 8-K) NOTICE OF GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 30, 2025 PROXY FORM (CLICK TO VIEW AND DOWNLOAD) ANNUAL …
